BnSellit Technology Inc. Announces Additional Rooms

Calgary, Alberta--(Newsfile Corp. - July 27, 2022) - BnSellit Technology Inc. (CSE: BNSL) ("BnSellit" or the "Corporation") is pleased to announce that it has added an additional 3,615 rooms between July 11, 2022 and July 22, 2022, bringing its total room count to 9,201. New hotels subscribing to the BnSellit services include brand name properties in Fort Myers, Sarasota, The Keys, Florida City, Miami, Tampa, Lakeland, Mystic Connecticut, Nashville, Florence KY, Shenandoah TX, Mason OH and Rancho Cordova CA. These are in addition to the Hotels added in New York City, Brooklyn NY, Jersey City NJ, Toronto, Niagara and various cities in Quebec, previously reported in recent press releases.

"We are excited to see the BNSL network of hotel subscribers expand beyond our initial targeted market areas to include properties across the US. Demand for the BNSL services continues to be robust and we expect to continue to add hotel subscribers at an accelerated rate in the coming weeks," said Tony Comparelli, CEO of BnSellit Technology Inc.

For further information, please contact:

Antonio Comparelli, Chief Executive Officer
Email: [email protected]
Tel: 416-720-8677

Corey Heerensperger, Chief Financial Officer
Email: [email protected]
Tel: 403-630-2779

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/132117

You May Also Be Interested In

• Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
• ONAR Holding Corporation Returns to Current SEC Reporting Status and Reports Fiscal Year 2025 and First Quarter 2026 Results
• Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease